CN Patent

CN112423754A — 阿立哌唑的给药策略

Assigned to Alkermes Pharma Ireland Ltd · Expires 2021-02-26 · 5y expired

What this patent protects

本发明涉及使用阿立哌唑、月桂酰阿立哌唑和月桂酰阿立哌唑纳米颗粒分散体的组合治疗精神分裂症的方法。

USPTO Abstract

本发明涉及使用阿立哌唑、月桂酰阿立哌唑和月桂酰阿立哌唑纳米颗粒分散体的组合治疗精神分裂症的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN112423754A
Jurisdiction
CN
Classification
—
Expires
2021-02-26
Drug substance claim
No
Drug product claim
No
Assignee
Alkermes Pharma Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.